Access Tomorrow’s Treatments Today

Empowering patients with cutting-edge radiopharmaceutical therapies, close to home.

Search Active TrialsTalk To A Clinical Navigator

Clinical Trials That Put Patients First

At United Theranostics, clinical trials are more than research, they are care. By integrating advanced radiopharmaceutical therapies with patient-centric support, we deliver local access to life-changing treatments while ensuring excellence at every step.

  • Advanced Theranostic Therapies
  • Local Centers with Global Expertise
  • Trust, Transparency, and Compassion
  • Seamless Participation & Retention Programs

Explore Our Active Clinical Trials

[68Ga]Ga-R12961 | Head, Neck, Gastric, Colorectal, Breast, Pancreatic, Skin | Radionetics Oncology

View Details


Title: Phase 1 Imaging Study of [68Ga]Ga-R12961 in Advanced Solid Tumors

Sponsor: Radionetics Oncology

Description: This is an open-label, first-in-human, Phase 1 study of [68Ga]Ga-R12961 designed to characterize its safety, biodistribution, tumor detection capability, radiation dosimetry, and PK in participants with advanced solid tumors including head and neck squamous cell  carcinoma, gastric cancer, colorectal cancer, and any other metastatic solid tumor, for example NSCLC, breast cancer, pancreatic cancer, and melanoma.

Number of patients to be enrolled (study wide): 32

Patient Eligibility Criteria:
This information is not yet available on the clinicaltrials.gov website. 

If you are interested in more information about this trial:
Please fill out this form.

[225Ac]Ac-AKY-1189 | Bladder, Urothelial, Breast, Lung, Cervical, Colorectal, Head and Neck | Aktis Oncology, Inc.

View Details


Title: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Sponsor: Aktis Oncology, Inc.

Description: This study consists of two parts (Part 1 and 2).

Part 1 is the dose escalation portion of the study, which will investigate ascending doses of [225Ac]Ac-AKY-1189 (up to 6 cycles) in patients with locally advanced or metastatic solid tumors. The aim of Part 1 is to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.

Part 2 will be the dose expansion portion of the study and will enroll locally advanced or metastatic solid tumor patients who are identified as Nectin-4 positive by [64Cu]Cu-AKY-1189. Part 2 aims to further assess the efficacy of [225Ac]Ac-AKY-1189 at the RP2D in 3 different cohorts of patients.

Number of patients to be enrolled (study wide): 150

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

CLR 125 | Breast | Cellectar

View Details

Title: A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients with Relapsed or Refractory Triple Negative Breast Cancer

Sponsor: Cellectar

Description: A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients with Relapsed or Refractory Triple Negative Breast Cancer

Number of patients to be enrolled (study wide): 75

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

View Details

Title: Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (Solar-Stage)

Sponsor: Curium US LLC

Description:This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Number of patients to be enrolled (study wide): 439

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[225Ac]Ac-PSMA-I&T | Prostate | Fusion Pharmaceuticals Inc.

View Details

Title: FPI-2265 ([225Ac]Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (AlphaBreak)

Sponsor: Fusion Pharmaceuticals Inc.

Description: This is an open-label, randomized, multicenter study of FPI-2265 ([225Ac]Ac-PSMA-I&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with [177Lu]Lu-PSMA-617 or another [177Lu]Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regimen of FPI-2265.

Number of patients to be enrolled (study wide): 610

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[111In]In-MC-760 | Esophageal, Breast, Lung & Prostate | Mariana Oncology

View Details

Title: A Phase 0 study of [111In]In-MC-760 in Patients with Solid Tumors that Commonly Express B7-H3.

Sponsor: Mariana Oncology

Description: A Phase 0, open-label first-in-human study to evaluate the biodistribution, safety, tolerability, pharmacokinetics, and radiation dosimetry of [111In]In-MC-760 in adult patients with solid tumors that commonly express B7-H3

Number of patients to be enrolled (study wide): ~14

Patient Eligibility Criteria:
Patients with solid tumors commonly expressing B7-H3 with archival tumor tissue available for retrospective evaluation

If you are interested in more information about this trial:
Please fill out this form.

LY4337713 | FAP+ Solid Tumors | Eli Lilly

View Details

Title: Phase 1a/1b Study to Evaluate Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)

Sponsor: Eli Lilly

Description: This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Number of patients to be enrolled (study wide): ~241

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[212Pb]Pb-DOTAM-GRPR1 | Prostate, Breast, Colorectal, Cervical, Melanoma & Lung | Orano Med LLC

View Details

Title: Safety and Tolerability of [212Pb]Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor: Orano Med LLC

Description: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of [212Pb]Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Number of patients to be enrolled (study wide): 30

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[68Ga]Ga-R11228 & [177Lu]Lu-R11228 | Breast | Radionetics Oncology

View Details

Title: A Phase 1 Study of [68Ga]Ga-R11228 and [177Lu]Lu-R11228 in Breast Cancer

Sponsor: Radionetics Oncology

Description: Part A is being conducted to test [68Ga]Ga-R11228, a new investigational product (IP) that has been designed to detect cancer lesions in the body and make them visible on a Positron Emission Tomography (PET) scan. Three dose levels of [68Ga]Ga-R11228 will be evaluated, with each patient receiving a single dose. Part B is being conducted to test [68Ga]Ga-R11228 and additionally [177Lu]Lu-R11228, which has been designed to treat patients who have cancer lesions with positive uptake on PET scan using [68Ga]Ga-R11228. Patients who qualify for [177Lu]Lu-R11228 treatment will receive up to 6 doses over approximately 36 weeks. Multiple [177Lu]Lu-R11228 dose levels will be evaluated in Part B.

Number of patients to be enrolled (study wide): 12

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

RYZ101 | Neuroendocrine | RayzeBio, Inc.

View Details

Title: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following [177Lu]Lu-SSA Therapy (ACTION-1)

Sponsor: RayzeBio, Inc.

Description: This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue ([177Lu]Lu-SSA) therapy, such as [177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC ([177Lu]Lu-DOTATATE/TOC), or [177Lu]Lu-high affinity [HA]-DOTATATE.

Number of patients to be enrolled (study wide): ~288

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[89Zr]Zr-DFO-girentuximab | Renal Cell | Telix Pharmaceuticals (Innovations) Pty Limited

View Details

Title: [89Zr]Zr-DFO-girentuximab Expanded Access Program (EAP)

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

Description: The purpose of this Expanded Access Program (EAP) is to enable the use of [89Zr]Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Number of patients to be enrolled (study wide): ~100+

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[177Lu]Lu-TLX591 | Prostate | Telix Pharmaceuticals (Innovations) Pty Limited

View Details

Title: The Study of [177Lu]Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

Description: The purpose of this study is to evaluate the efficacy and safety of [177Lu]Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Number of patients to be enrolled (study wide): ~430

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

[212Pb]Pb-DOTAM-MAM279 | Lung, Stomach, Pancreatic, Bladder, Small Bowel, Neuro-endocrine, Cervical | Molecular Partners

View Details

Title: A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Sponsor: Molecular Partners AG

Description: The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Number of patients to be enrolled (study wide): 138

Patient Eligibility Criteria:
If you want to know more about the study, review the complete details on ClinicalTrials.gov

If you are interested in more information about this trial:
Please fill out this form.

Why Join a Clinical Trial?

  • Access new treatments before they are widely available.
  • Receive expert care from top specialists.
  • Help advance future medicine for others.
See if You’re Eligible

From Application to Care – What to Expect

Submit Interest or Referral

Submit Interest or Referral

Start by expressing your interest or having your healthcare provider refer you to one of our trials. Our team will review your information and guide you on the next steps. It's quick and confidential.
Pre-screening & Eligibility Check
Pre-screening & Eligibility Check
We conduct a thorough review of your medical history and may request lab tests to determine your eligibility. This step ensures the trial is a good match for your specific type of cancer. Our goal is to prioritize your safety and the potential for benefit.
Enrollment & Onboarding
Enrollment & Onboarding
Once you're eligible, we'll walk you through the enrollment process, including any paperwork and consent forms. Our staff will explain the study in detail so you know what to expect. You'll have the opportunity to ask questions at every stage.
Treatment & Follow-up
Treatment & Follow-up
You will begin receiving the trial treatment under close medical supervision. Our care team monitors your progress closely, adjusting as needed and supporting your comfort throughout. Regular follow-up visits help us track results and ensure your well-being.
Continued Support & Care

Continued Support & Care

Even after your participation ends, we stay connected. We offer guidance, coordinate with your primary care team, and provide access to additional resources. Your long-term health and support remain our priority.

World-Class Care Teams at Your Side

Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI

Dr. Babak Saboury, MD, MPH, DABR, DABNM

Dr. Eliot Siegel, MD, FACR, FSIM, DABR

Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI

Dr. Olga Molchanova-Cook, MD, PhD

Powered by Precision and Compassion

  • Uni-Claude™ AI platform for centralized operations
  • Dosimetry expertise
  • Regulatory harmonization
  • First to deliver alpha dosimetry with Actinium-225

Frequently Asked Questions

B
C

What is a radiopharmaceutical clinical trial?


A radiopharmaceutical clinical trial studies new cancer treatments that use targeted radioactive medicines known as radiopharmaceuticals to find and treat cancer cells. These trials evaluate the safety and effectiveness of advanced therapies, often combining precise molecular imaging with treatment. United Theranostics specializes in these trials, offering patients access to the latest innovations in targeted cancer care.
B
C

Will I have to travel far?


United Theranostics operates clinics in the following locations to make participation as accessible as possible:

  • Glen Burnie, MD
  • Princeton, NJ
  • Las Cruces, NM

We match participants to the nearest clinic whenever possible. In some cases, travel may be necessary if a specific trial is only available at a certain location. Our team will work with you to minimize travel and support your participation throughout the process.

B
C

Are there costs to participate?

Most clinical trials cover the costs of study-related treatments and required tests. Additional support, such as insurance assistance and financial aid, is often available. Before enrolling, our team will review any potential costs and available resources with you, ensuring you have a clear understanding of what to expect.
For more information about patient support services, you can also contact us at (800) 898-2650.

Talk to Our Clinical Trial Navigators

Fill out the form to schedule your personalized consultation.

Name(Required)